Anti-CRYAB monoclonal antibody
Pre-made anti-CRYAB monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research
Go to CRYAB/CRYAB products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-IP0616-Ab-1/ GM-Tg-hg-IP0616-Ab-2 | Anti-Human CRYAB monoclonal antibody | Human |
GM-Tg-rg-IP0616-Ab-1/ GM-Tg-rg-IP0616-Ab-2 | Anti-Rat CRYAB monoclonal antibody | Rat |
GM-Tg-mg-IP0616-Ab-1/ GM-Tg-mg-IP0616-Ab-2 | Anti-Mouse CRYAB monoclonal antibody | Mouse |
GM-Tg-cynog-IP0616-Ab-1/ GM-Tg-cynog-IP0616-Ab-2 | Anti-Cynomolgus/ Rhesus macaque CRYAB monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-IP0616-Ab-1/ GM-Tg-felg-IP0616-Ab-2 | Anti-Feline CRYAB monoclonal antibody | Feline |
GM-Tg-cang-IP0616-Ab-1/ GM-Tg-cang-IP0616-Ab-2 | Anti-Canine CRYAB monoclonal antibody | Canine |
GM-Tg-bovg-IP0616-Ab-1/ GM-Tg-bovg-IP0616-Ab-2 | Anti-Bovine CRYAB monoclonal antibody | Bovine |
GM-Tg-equg-IP0616-Ab-1/ GM-Tg-equg-IP0616-Ab-2 | Anti-Equine CRYAB monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-IP0616-Ab-1/ GM-Tg-hg-IP0616-Ab-2; GM-Tg-rg-IP0616-Ab-1/ GM-Tg-rg-IP0616-Ab-2; GM-Tg-mg-IP0616-Ab-1/ GM-Tg-mg-IP0616-Ab-2; GM-Tg-cynog-IP0616-Ab-1/ GM-Tg-cynog-IP0616-Ab-2; GM-Tg-felg-IP0616-Ab-1/ GM-Tg-felg-IP0616-Ab-2; GM-Tg-cang-IP0616-Ab-1/ GM-Tg-cang-IP0616-Ab-2; GM-Tg-bovg-IP0616-Ab-1/ GM-Tg-bovg-IP0616-Ab-2; GM-Tg-equg-IP0616-Ab-1/ GM-Tg-equg-IP0616-Ab-2 |
Products Name | Anti-CRYAB monoclonal antibody |
Format | mab |
Target Name | CRYAB |
Protein Sub-location | Introcelluar Protein |
Category of antibody | |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected. |
Tag | Fc |
Products description | Pre-made anti-CRYAB monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | GM-Tg-g-IP0616-Ag-1 | Recombinant multi-species CRYAB/ CMD1II/ CRYA2 protein |
ORF Viral Vector | vGMLP002745 | human CRYAB Lentivirus particle |
ORF Viral Vector | pGMLP002745 | human CRYAB Lentivirus plasmid |
ORF Viral Vector | vGMLV000870 | human CRYAB Lentivirus particle |
ORF Viral Vector | pGMLV000870 | human CRYAB Lentivirus plasmid |
ORF Viral Vector | pGMLPm000066 | mouse Cryab Lentivirus plasmid |
ORF Viral Vector | vGMLPm000066 | mouse Cryab Lentivirus particle |
Target information
Target ID | GM-IP0616 |
Target Name | CRYAB |
Gene ID | 1410,12955,25420,710747,479441,101092640,281719,100061921 |
Gene Symbol and Synonyms | AACRYA,CMD1II,Crya-2,CRYA2,CRYAB,CTPP2,CTRCT16,HEL-S-101,HSPB5,MFM2,P23 |
Uniprot Accession | P02511,P23928,P02510 |
Uniprot Entry Name | CRYAB_HUMAN,CRYAB_RAT,CRYAB_BOVIN |
Protein Sub-location | Introcelluar Protein |
Category | |
Disease | Breast Cancer |
Gene Ensembl | ENSG00000109846 |
Target Classification | N/A |
The target: CRYAB, gene name: CRYAB, also named as CMD1II, CRYA2, CTPP2, CTRCT16, HEL-S-101, HSPB5, MFM2. Mammalian lens crystallins are divided into alpha, beta, and gamma families. Alpha crystallins are composed of two gene products: alpha-A and alpha-B, for acidic and basic, respectively. Alpha crystallins can be induced by heat shock and are members of the small heat shock protein (HSP20) family. They act as molecular chaperones although they do not renature proteins and release them in the fashion of a true chaperone; instead they hold them in large soluble aggregates. These heterogeneous aggregates consist of 30-40 subunits; the alpha-A and alpha-B subunits have a 3:1 ratio, respectively. Two additional functions of alpha crystallins are an autokinase activity and participation in the intracellular architecture. The encoded protein has been identified as a moonlighting protein based on its ability to perform mechanistically distinct functions. Alpha-A and alpha-B gene products are differentially expressed; alpha-A is preferentially restricted to the lens and alpha-B is expressed widely in many tissues and organs. Elevated expression of alpha-B crystallin occurs in many neurological diseases; a missense mutation cosegregated in a family with a desmin-related myopathy. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jan 2019].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.